ReviewMedComm2025
UFMylation System: Biological Functions, Molecular Mechanisms, Diseases, and Drug Discovery.
Review in MedComm, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Exploring the potential involvement of UFSP2 in spindle assembly checkpoint regulation in breast cancer.Molecular biology reports · 2026Article
- Optimization of protein UFMylation modification method and its application in substrate identification in human cells.The Journal of biological chemistry · 2026Article
- The UFL1-AKT positive feedback loop promotes breast cancer progression by enhancing lipid synthesis.Nature communications · 2026Article
- An integrative analysis of UFMylation-related genes reveals a prognostic signature and identifies GDF7 as a novel therapeutic target in gastric cancer.Frontiers in oncology · 2026Article
- Identifying of Ubiquitin-Fold Modifier 1 as a Potential Prognostic Biomarker for Unresectable Pancreatic Cancer by Proteomics Analysis.Cancer management and research · 2026Article
- UFMylation System: Biological Functions, Molecular Mechanisms, Diseases, and Drug Discovery.MedComm · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
UFMylation, a novel ubiquitin-like modification, plays a critical role in various intertwined cellular processes, such as the immune response, DNA damage repair, unfolded protein response (UPR), autophagy, endoplasmic reticulum (ER)-phagy, stem cell self-renewal, apoptosis, and metastasis. Dysfunction of UFMylation has been implicated in a variety of human diseases, including neurogenesis, hematopoiesis, liver development, and cancer. While this field is just emerging, research on UFMylation has escalated rapidly in recent years, with great advances having been made. However, only a few substrates of UFMylation have been identified so far, and the biological functions as well as the molecular mechanisms of the UFMylation system in tumorigenesis and the tumor microenvironment remain poorly understood. In this review, we first summarize current knowledge of the components, biochemical peculiarities, and working principles of the UFMylation system. Second, we provide a multidisciplinary review of the cellular functions, molecular mechanisms, and pathophysiological roles of the UFMylation system, with a particular emphasis on the intricate relationship between UFMylation and cancer. Finally, we discuss the potential of targeting UFMylation in cancer treatment and highlight outstanding questions for future investigation in this field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.